Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

NCT05088369 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis
Crohn's Disease

Interventions

DRUG: HM201
DRUG: Placebo
DRUG: HM201
DRUG: Placebo

Sponsor

Syneos Health

Collaborators

[object Object]